Recent claims in the lay press that rasagiline (N-propargyl-1[R]-aminoindan) mesylate (TVP-1012) can reduce the progressive functional decline in patients with Parkinson disease prompted a colleague to ask me to look again at the article reporting the results of the TEMPO study.1 Examination of the article raised a concern regarding the inclusion of certain subjects in the primary analysis.
Shults CW. Reexamination of the TEMPO Study. Arch Neurol. 2005;62(8):1320. doi:10.1001/archneur.62.8.1320